patent.fyi
Applications  /  US 2026/0355275
United States Patent Application Publication

US 2026/0355275 A1

Published
Nov 12, 2026
Filed
May 5, 2025
Earliest date on the face
May 5, 2025
Classification
A61K 38/16
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Neutralize a niche signal

What ifWhat if an antibody that binds interleukin-6 serves as the first active ingredient?
Claim language“Ganoderma immunomodulatory protein (GMI), a recombinant thereof or a fragment thereof”

The antibody binds soluble interleukin-6 and reduces its availability to the interleukin-6 receptor. In interleukin-6-dependent tumor cultures, this reduces downstream STAT3 phosphorylation and dampens a signal that supports self-renewal.

1.1Suppress beta-catenin expression

What ifWhat if lipid nanoparticles carrying small interfering RNA against beta-catenin serve as the first active ingredient?
Claim language“Ganoderma immunomodulatory protein (GMI), a recombinant thereof or a fragment thereof”

An ionizable lipid nanoparticle carries the RNA duplex into cells by endocytosis and releases a fraction of the duplex into the cytosol. The guide strand directs cleavage of beta-catenin messenger RNA, reducing beta-catenin-dependent transcription in responsive tumor cells.

1.2Inhibit aldehyde detoxification

What ifWhat if a small-molecule ALDH1A1 inhibitor serves as the second active ingredient?
Claim language“salvianolic acid B or a pharmaceutical acceptable salt thereof”

The inhibitor reduces ALDH1A1-mediated oxidation of reactive aldehydes to carboxylic acids. In tumor cells that rely on this enzyme for aldehyde detoxification, inhibition increases aldehyde stress and decreases cell survival.

1.2Induce retinoid receptor signaling

What ifWhat if all-trans retinoic acid serves as the second active ingredient?
Claim language“salvianolic acid B or a pharmaceutical acceptable salt thereof”

All-trans retinoic acid binds nuclear retinoic acid receptors and changes transcription at retinoic acid response elements. In retinoid-responsive tumor cells, the transcriptional response promotes differentiation and reduces the fraction of cells that retain an immature phenotype.

1.2Inhibit focal adhesion signaling

What ifWhat if an ATP-competitive focal adhesion kinase inhibitor serves as the second active ingredient?
Claim language“salvianolic acid B or a pharmaceutical acceptable salt thereof”

The inhibitor occupies the kinase ATP-binding site and reduces focal adhesion kinase autophosphorylation at tyrosine 397. In tumor cells that rely on integrin-mediated survival signals, this reduces downstream signaling that supports survival in three-dimensional cultures.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Specific version of a part

Full-length recombinant fungal protein

A bacterial expression system produces the full-length coding sequence of the fungal immunomodulatory protein with a removable polyhistidine tag. Immobilized metal affinity chromatography captures the tagged protein, and protease cleavage removes the tag before final purification.

Freeze-dried recombinant protein

A buffered solution contains purified full-length recombinant protein, histidine buffer at pH 6.0, and trehalose. Freeze-drying removes water, and sterile water restores the formulation to its original fill volume before use.

Free acid in solution

Purified salvianolic acid B in its free acid form dissolves in a citrate-buffered aqueous vehicle at pH 4.5. An amber vial limits light exposure, and a liquid chromatography assay measures active ingredient concentration and tracks degradation products.

Disodium salt powder

Two molar equivalents of sodium hydroxide neutralize the two carboxylic acid groups of salvianolic acid B in water. Freeze-drying yields a disodium salt powder that redissolves in an aqueous vehicle.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,623,074 B2
Published
Apr 18, 2017
Filed
Feb 26, 2013
Class
A61K 38/16
Document BUS 10,300,030 B2
Published
May 28, 2019
Filed
Aug 28, 2014
Class
A61K 31/192
Claim 1
Document A
Document B
1.1Ganoderma immunomodulatory protein (GMI), a recombinant thereof or a fragment thereof; and
No. 7,601,808 discloses an immunomodulatory protein (GMI) cloned from Ganoderma microsporum and this protein has immunomodulator efficiency.
A · US 9,623,074 B2 · ¶ 5
1.2salvianolic acid B or a pharmaceutical acceptable salt thereof.
Danshensu:protocatechuic acid:protocatechuic aldehyde:caffeic acid:Salvianolic acid U+ Salvianolic acid T:rosmarinic acid:lithospermic acid:Salvianolic acid B:Salvianolic acid A:Salvianolic acid G isomer:Salvianolic acid G:Salvianolic D=(2˜6):(0.01˜0.05):(1˜3):(0.01˜0.06):(0.5˜2):(0.2˜1):(0.05˜0.3):(0.5˜2):(0.2˜1):(0.1˜0.5):(0.1˜0.5):(0.2˜1).
B · US 10,300,030 B2 · ¶ 11

An empty cell means only that no passage was reproduced there.

Statements in these documents
During human skin wound healing, a critical rate-limiting step is the initiation of the resident epidermal and dermal cells at the wound edge to migrate into the wound bed.
A · US 9,623,074 B2 · ¶ 3
The invention provides a method for promoting healing of a wound or treating a tissue injury in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more fungal immunomodulatory protein immunomodulatory protein or a fragment or variant thereof.
A · US 9,623,074 B2 · ¶ 7
More specifically, the invention relates to a traditional Chinese medicine composition for treating cardiovascular disease and a preparation thereof.
B · US 10,300,030 B2 · ¶ 2
However, due to the stronger toxicity and side effect, these drugs are not suitable to use for long time.
B · US 10,300,030 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355275 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355275/, SHA-256 2d3c8ab0717a4a97bbbef9c1fd172302eca991662302724cca39ea6ef6f8064b
First published
Permanent addresshttps://patent.fyi/US20260355275/
Content fingerprint (SHA-256)2d3c8ab0717a4a97bbbef9c1fd172302eca991662302724cca39ea6ef6f8064b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi